The Online Investor
Daily M&A
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Fri., Sep. 19, 3:52 PM

Slide #3. Horizon Pharma Vidara Therapeutics International plc

Acquirer: Horizon Pharma (NASDAQ:HZNP)
Acquiree: Vidara Therapeutics International plc
Details: Horizon Pharma (NASDAQ: HZNP) announced today it has completed the acquisition of Vidara Therapeutics International plc. In connection with the acquisition, Horizon and Vidara have combined with the resulting parent company incorporated in Ireland and named Horizon Pharma Public Limited Company, or plc. The acquisition further accelerates Horizon's transformation into a profitable specialty biopharmaceutical company and provides a strong operating and financial platform for future growth. The Company has over 500 employees globally, including a U.S. commercial organization focused on primary care, specialty and rare diseases. In addition to its headquarters in Dublin, Ireland, the Company also has offices in Deerfield, Illinois; Roswell, Georgia; Reinach, Switzerland and Mannheim, Germany.

Horizon Pharma is a holding company. Through its subsidiaries, Co. is commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets therapeutic needs in arthritis, pain and inflammatory diseases. Co. developed DUEXIS and RAYOS/LODOTRA. DUEXIS is a single tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. Co.'s second approved product in the U.S., RAYOS, known as LODOTRA outside the U.S., is a delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active rheumatoid arthritis in adults, particularly when accompanied by morning stiffness. Co. acquired the U.S. rights to VIMOVO from AstraZeneca AB.

Open the HZNP Page at The Online Investor »

Company Name:  Horizon Pharma Plc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding HZNP:  19
Total Market Value Held by ETFs:  $59.40M
Total Market Capitalization:  $919.00M
% of Market Cap. Held by ETFs:  6.46%

Open the HZNP Page at The Online Investor (in a new window) »

September 19, 2014    3:52 PM Eastern
Quotes delayed 20 minutes

Strong Buy (3.60 out of 4)
76th percentile
(ranked higher than approx. 76% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.